Disease Landscape and Forecast 인사이트

The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…

Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…

Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…

To view the recording from our webinar series, please select the video link to the left   Outline – Background – Overarching theme of the EGA conference – Current and future startegies to drive…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…

Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…

Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…

Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…